



Docket No.: C35795/1123

162316
RECEIVED
MAR 28 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Jerome CANTOR, et al.) Examiner: To be Assigned
)
Serial No.: 09/863,849) Group Art Unit: 1623
)
Filed: May 23, 2001)

For: METHOD FOR TREATING RESPIRATORY DISORDERS
ASSOCIATED WITH PULMONARY ELASTIC FIBER INJURY

March 12, 2002

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Box DD
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants wish to make of record the following documents (clean copies and a Form PTO-1449 listing the documents are enclosed). The following documents were cited in the International Search Report, January 10, 2002, in the International application corresponding to the above-captioned case.

U.S. PATENT DOCUMENTS

<u>Patent No.</u>	<u>Issue Date</u>	<u>Author</u>
4,496,689	1/29/1985	Mitra
5,668,118	9/16/1997	Kennedy
5,690,910	11/25/1997	Ahmed, et al.

FOREIGN PATENT DOCUMENTS

<u>Patent No.</u>	<u>Publication Date</u>	<u>Country</u>
97/33592	9/1997	WO
98/11066	3/1998	WO
99/06025	2/1999	WO
00/44367	8/2000	WO

OTHER PUBLICATIONS


- International Search Report, dated January 10, 2001;
- Patent Abstracts of Japan, publication no. 11147901, published February 6, 1997;
- Patent Abstracts of Japan, publication no. 11269077, published October 5, 1999;
- Cantor, et al., "The Effect of Hyaluronan on Elastic Fiber Injury *In Vitro* and Elastase-Induced Airspace Enlargement *In Vivo*," HA Prevents Elastic Fiber Injury, pp. 65-71 (2000);
- Frommherz, et al., "Effect of Sulfated Glycosaminoglycans on the Inhibition of Neutrophil Elastase by α_1 -Proteinase Inhibitor," New Aspects of Human Polymorphonuclear Leukocytes, pp. 161-165 (1991).


The Examiner's independent consideration of all these documents and their relevance is respectfully requested. The Examiner is also requested to initial and return copies of the accompanying PTO 1449 forms to evidence such consideration.

This Information Disclosure Statement is being filed in accordance with the provisions under 37 C.F.R. §1.97(b)(3). To the best of the undersigned's knowledge, before the mailing of a first Office Action on the merits. No fee is required.

The Commissioner is hereby authorized to charge any fees which are due to
Deposit Account No. 02-4467.

Respectfully submitted,

By: 
Charles T. J. Weigell
Reg. No. 43,398
BRYAN CAVE LLP
245 Park Avenue
New York, New York 10167-0034
(212) 692-1800

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: BOX DD, Assistant Commissioner for Patents, Washington, D.C. 20231, on March 12, 2002
(Date of Deposit)
Charles T. J. Weigell
Name of applicant, assignee, or Registered Representative
 Signature
3/12/02
Date of Signature